文献速递鼻科

局部鼻用可卡因用于鼻窦手术的随机III期临床试验

Investigation of topical intranasal cocaine for sinonasal procedures: a randomized, phase III clinical trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2020-05-08

这项III期随机双盲多中心安慰剂和剂量对照平行组研究评估了局部鼻用可卡因(RX0041-002)的安全性和有效性。648例受试者随机接受安慰剂(95例)、4%可卡因(275例)或8%可卡因(278例)。4%和8%可卡因均达到显著的主观镇痛主要疗效终点,安全性和耐受性良好,不良事件谱与安慰剂相似。

要点

  • 4%和8%局部鼻用可卡因均能提供显著的主观镇痛效果。
  • 两剂量安全性良好,未发生心血管不良事件、严重不良事件或死亡。
  • 4%和8%组较安慰剂组有更高比例受试者出现收缩压或舒张压轻度升高。

核心结论

  • 局部4%和8%可卡因是可用于鼻部手术的有效麻醉剂,给药安全。

研究设计与样本

  • III期、随机、前瞻性、双盲、多中心、单剂量、安慰剂和剂量对照、平行组研究。
  • 共筛选925例受试者,随机648例:安慰剂95例,4% RX0041-002 275例,8% RX0041-002 278例。
  • 疗效采用视觉数字评分量表评估主观疼痛强度,并采用von Frey纤维丝测试客观评估。

主要发现

  • 4%和8%可卡因均达到显著受试者镇痛的主要疗效终点。
  • 两剂量安全且耐受性良好,安全性特征与安慰剂相似。
  • 4%和8%组中仅头痛(分别为1.5%和2.5%)、鼻出血(0.7%和1.1%)和焦虑(0.7%和0%)被超过1例受试者报告。
  • 未发生心血管不良事件、严重不良事件或死亡。
  • 4%和8%组较安慰剂组有更高比例受试者出现收缩压或舒张压轻度升高。

关键数值与推荐

  • 主要疗效终点为主观镇痛,采用视觉数字评分量表评估。
  • 客观评估采用von Frey纤维丝测试。
  • 安慰剂组与实验组比较采用双侧Fisher精确检验。

临床怎么用

  • 局部4%和8%可卡因可用于鼻部手术麻醉,需注意血压轻度升高的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this trial was to demonstrate the clinical efficacy and safety of topical cocaine as part of the effort to gain regulatory approval from the United States Food and Drug Administration. METHODS: This phase III, randomized, prospective, double-blind, multicenter, single-dose, placebo- and dose-controlled, parallel-group study aimed to evaluate the safety and efficacy of topical intranasal cocaine (RX0041-002). A total of 925 subjects were screened and a total of 648 subjects were randomized: 95 to placebo; 275 to 4% RX0041-002; and 278 to 8% RX0041-002. Efficacy was assessed with subjective pain intensity scores using the visual numeric rating scale and objectively using the von Frey filament test. Adverse events (AEs), vital signs, Holter monitoring, nasal irritation on visual examination, and smell assessment were recorded. The placebo and experimental groups were compared using a two-tailed Fisher's exact test. RESULTS: Topical 4% and 8% cocaine achieved significant subject analgesia, the primary efficacy endpoint. Both doses were safe and well-tolerated, with a safety profile similar to placebo. In the 4% and 8% groups, headache (1.5% and 2.5%, respectively), epistaxis (0.7% and 1.1%), and anxiety (0.7% and 0%) were the only AEs reported by >1 subject. No cardiovascular AEs, serious AEs, or deaths occurred. A higher percentage of subjects in the 4% and 8% groups compared with the placebo group had a modest increase in either systolic or diastolic blood pressure. CONCLUSION: Topical 4% and 8% cocaine is an effective anesthetic that can be safely administered for nasal procedures.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. McGrath J, McGrath A, Burdett J, et al. Investigation of topical intranasal cocaine for sinonasal procedures: a randomized, phase III clinical trial. Int Forum Allergy Rhinol. 2020. PMID: 32384578. doi:10.1002/alr.22561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。